Bayer today announced a partnership with Impli, an innovative, deep-tech start-up in precision care. Impli’s goal is to advance women’s health and deliver the first real-time hormone monitoring device – making fertility more accessible, safer and more successful.

Grifols a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has established a partnership with the Biomedical Advanced Research and Development Authority (BARDA)

The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine whether opaganib can advance into further definitive U.S. government-sponsored development under the FDA's Animal Rule pathway to approval

Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

AstraZeneca and Ionis’ Wainzua (eplontersen) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis

Evosep, a global leader in proteomics solutions, is proud to announce its relocation to new headquarters in Odense.

The 55th Zhangshu National Traditional Chinese Materia Medica Trade Fair in Zhangshu, a county-level city in east China's Jiangxi Province.

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today that the first participant has been dosed in the Randomized Placebo Controlled Double Blind Phase I-IIa ArthemiR

Today, Allergan Aesthetics, an AbbVie company announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults.

Avadel Pharmaceuticals plc a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy.